S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
Critical asset just had biggest fall on record (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
Critical asset just had biggest fall on record (Ad)
South Korean doctors hold massive anti-government rally over medical school recruitment plan
What to watch for as China's major political meeting of the year gets underway

Agape ATP (ATPC) Competitors

$0.36
-0.01 (-2.73%)
(As of 03/1/2024 ET)

ATPC vs. EUDA, BTTX, KA, GDTC, SABS, VIRX, FEMY, NKGN, SLGL, and NRBO

Should you be buying Agape ATP stock or one of its competitors? The main competitors of Agape ATP include EUDA Health (EUDA), Better Therapeutics (BTTX), Kineta (KA), CytoMed Therapeutics (GDTC), SAB Biotherapeutics (SABS), Viracta Therapeutics (VIRX), Femasys (FEMY), NKGen Biotech (NKGN), Sol-Gel Technologies (SLGL), and NeuroBo Pharmaceuticals (NRBO). These companies are all part of the "medical" sector.

Agape ATP vs.

Agape ATP (NASDAQ:ATPC) and EUDA Health (NASDAQ:EUDA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Agape ATP
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
EUDA Health
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

EUDA Health has a net margin of 0.00% compared to Agape ATP's net margin of -130.27%. EUDA Health's return on equity of 0.00% beat Agape ATP's return on equity.

Company Net Margins Return on Equity Return on Assets
Agape ATP-130.27% -191.90% -87.18%
EUDA Health N/A N/A N/A

Agape ATP and EUDA Health both received 0 outperform votes by MarketBeat users.

CompanyUnderperformOutperform
Agape ATPN/AN/A
EUDA HealthN/AN/A

35.0% of EUDA Health shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Agape ATP has higher earnings, but lower revenue than EUDA Health.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Agape ATP$1.86M14.76-$1.69M-$0.02-17.81
EUDA Health$9.84M3.43-$24.88MN/AN/A

In the previous week, EUDA Health had 1 more articles in the media than Agape ATP. MarketBeat recorded 3 mentions for EUDA Health and 2 mentions for Agape ATP. Agape ATP's average media sentiment score of 1.43 beat EUDA Health's score of 0.29 indicating that Agape ATP is being referred to more favorably in the media.

Company Overall Sentiment
Agape ATP Positive
EUDA Health Neutral

Summary

EUDA Health beats Agape ATP on 6 of the 9 factors compared between the two stocks.


Get Agape ATP News Delivered to You Automatically

Sign up to receive the latest news and ratings for ATPC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATPC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

ATPC vs. The Competition

MetricAgape ATPHealth services IndustryMedical SectorNASDAQ Exchange
Market Cap$27.46M$889.23M$5.09B$7.62B
Dividend YieldN/A1.64%2.82%3.87%
P/E Ratio-17.8137.53221.9117.05
Price / Sales14.762.383,097.17108.91
Price / CashN/A20.9099.9255.44
Price / BookN/A2.534.534.54
Net Income-$1.69M-$38.04M$114.85M$211.55M
7 Day Performance2.50%10.68%5.73%3.36%
1 Month Performance-31.06%17.86%12.81%6.70%
1 Year PerformanceN/A-4.71%12.92%7.44%

Agape ATP Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EUDA
EUDA Health
0 of 5 stars
$1.45
flat
N/A+15.1%$35.71M$7.55M0.00150Short Interest ↑
BTTX
Better Therapeutics
1.6674 of 5 stars
$0.17
-22.8%
$6.00
+3,437.7%
-84.0%$8.46MN/A-0.1554Short Interest ↑
Gap Up
High Trading Volume
KA
Kineta
3.1117 of 5 stars
$2.60
-8.1%
$8.00
+207.7%
-84.7%$27.02M$5.93M0.0011News Coverage
Gap Down
GDTC
CytoMed Therapeutics
0 of 5 stars
$2.44
+1.7%
$5.00
+104.9%
N/A$26.69MN/A0.00N/AShort Interest ↑
Gap Up
SABS
SAB Biotherapeutics
3.2255 of 5 stars
$5.24
-4.6%
$10.00
+90.8%
+548.6%$27.42M$23.90M0.0056News Coverage
VIRX
Viracta Therapeutics
2.376 of 5 stars
$0.71
+4.4%
$7.75
+991.5%
-46.8%$27.42MN/A-0.5741News Coverage
FEMY
Femasys
3.2503 of 5 stars
$1.23
-1.6%
$9.00
+631.7%
+73.1%$26.63M$1.21M-1.2734Short Interest ↓
News Coverage
NKGN
NKGen Biotech
0 of 5 stars
$1.26
-16.0%
N/AN/A$27.58MN/A0.00N/AUpcoming Earnings
Gap Up
SLGL
Sol-Gel Technologies
3.2261 of 5 stars
$1.20
+2.6%
$8.00
+566.7%
-75.1%$27.76M$3.88M-1.1055Upcoming Earnings
Short Interest ↑
Gap Up
NRBO
NeuroBo Pharmaceuticals
0.3344 of 5 stars
$5.35
+1.5%
N/A+8.3%$25.95MN/A0.002Short Interest ↑
News Coverage
Gap Down

Related Companies and Tools

This page (NASDAQ:ATPC) was last updated on 3/3/2024 by MarketBeat.com Staff